The anti-tumour effects of zoledronic acid

Journal of Bone Oncology

Volumn 3, Issue 1, 2014, Pages 25-35

  Zekria, Jamal ^a,c   Mansour, Maged ^b   Karim, Syed Mustafa ^a,c  

^a ALFAISAL UNIVERSITY   (Saudi Arabia)

^b Dr Erfan and Bagedo General Hospital   (South Africa)

^c King Faisal Specilalist Hospital Research Center MBC J64   (South Africa)

Author keywords

Angiogenesis; Antitumour; Apoptosis; Bisphosphonates; T cells; Zoledronic acid

Indexed keywords

CELECOXIB; CISPLATIN; CLODRONIC ACID; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; MEVALONIC ACID; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE METASTASIS; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DISORIENTATION; DRUG EFFECT; HUMAN; IMMUNE RESPONSE; LONG TERM SURVIVAL; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL;

EID: 84901660991     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2013.12.001     Document Type: Review

References (89)

1. Hosfield DJ, Zhang Y, Dougan DR, Broun A, Tari LW, Swanson RV, et al. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 2004;279(10):8526-9.
2. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int 2004;75(6):451-61.
3. Reinholz GG, Getz B, Sanders ES, Karpeisky MY, Padyukova N, Mikhailov SN, et al. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue. Breast Cancer Res Treat 2002;71(3):257-68
4. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, et al. Structure-Activityrelationships for inhibition offarnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296(2):235-42
5. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-Translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13(4):581-9
6. Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, et al. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 2010;24(1):233-9.
7. Koto K, Horie N, Kimura S, Murata H, Sakabe T, Matsui T, et al. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett 2009;274(2):271 -8.
8. Zwolak P, Manivel JC, Jasinski P, Kirstein MN, Dudek AZ, Fisher J, et al. Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines. J Bone Joint Surg Am 2010;92(1):162-8.
9. Tamura T, Shomori K, Nakabayashi M, Fujii N, Ryoke K, Ito H. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apop-Tosis in oral carcinoma cell lines. Oncol Rep 2011;25(4):1139-43.
10. Ullen A, Schwarz S, Lennartsson L, Kalkner KM, Sandstrom P, Costa F, et al. Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 2009;43(2):98-103.
11. Koizumi M, Nakaseko C, Ohwada C, Takeuchi M, Ozawa S, Shimizu N, et al. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells. Eur J Haematol 2007;79(5):382-91.
12. Di Salvatore M, Orlandi A, Bagala C, Quirino M, Cassano A, Astone A, et al. Anti-Tumour and anti-Angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 2011;44(2):139-46.
13. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, Scheper MA. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog 2011;10:2
14. Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kalkner KM, Lennernas B, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44(6):644-50.
15. Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, et al. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 2009;33(2):239-46.
16. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bispho-sphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001;84(8):1126-34.
17. Ozturk OH, Bozcuk H, Burgucu D, Ekinci D, Ozdogan M, Akca S, et al. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol Int 2007;31(9):1069-71.
18. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008;100(16):1167-78.
19. Neville-Webbe HL, Coleman RE, Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br JCancer 2010;102(6):1010-7.
20. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence-And schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005;113(3):364-71.
21. Charehbili Ayoub, van deVen Saskia, Gerrit-Jan Liefers. NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC) -A Dutch Breast Cancer Trialists' Group (BOOG) study. J Clin Oncol 2013;31(suppl) Abstract 1028.
22. Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer -Arando-mized biomarker pilot study. Clin Cancer Res 2013;19(10):2755-65.
23. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-Tumour activity in breast cancer. Br J Cancer 2010;102(7):1099-105.
24. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365 (15):1396-405.
25. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-6
26. Yamada J, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Asakage M, et al. Anti-Angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 2009;151(1):115-20.
27. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302(3):1055-61.
28. Ziebart T, Pabst A, Klein MO, Kammerer P, Gauss L, Brullmann D, et al. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig 2011;15(1):105-11.
29. Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, et al. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther 2012;13(14):1491-500.
30. Tsai S-H, Huang P-H, Chang W-C, Tsai H-Y, Lin C-P, Leu H-B, et al. Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PloS One 2012;7(7):e41065.
31. Stresing V, Fournier PG, Bellahcene A, Benzaid I, Monkkonen H, Colombel M, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 2011;48(2):259-66.
32. Kuroshima S, Elliott KW, Yamashita J. Effect of zoledronate on the responses of osteocytes to acute parathyroid hormone. CalcifTissue Int 2013;92(6):576-85.
33. Kobayashi Y, Hiraga T, Ueda A, Wang L, Matsumoto-Nakano M, Hata K, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 2010;28(2):165-75.
34. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, et al. Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-Angiogenic agents. Cancer Invest 2009;27(2):221-6.
35. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteone-crosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76(3):209-11.
36. David Roodman G. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer 2003;97(Suppl. 3):S733-8.
37. Corso A, Ferretti E, Lunghi M, Zappasodi P, Mangiacavalli S, De Amici M, et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005;104(1):118-25.
38. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57(18):3890-4.
39. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 1999;83 (2):263-9.
40. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98(3):698-705.
41. Clezardin P, Fournier P, Boissier S, Peyruchaud O. In vitro and in vivo antitumor effects of bisphosphonates. Curr Med Chem 2003;10(2):173-80.
42. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003;88(10):1631-40
43. Green Jr. Antitumor effects of bisphosphonates. Cancer 2003;97(Suppl. 3): S840-S847.
44. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004;10(13):4559-67.
45. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 2002;62(21):6015-20.
46. Clezardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65 (12):4971-4
47. Hasmim M, Bieler G, Ruegg C. Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. JThromb Haemost 2007;5(1):166-73
48. Bukowski JF, Morita CT, Tanaka Y, Bloom BR, Brenner MB, Band H. V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J Immunol 1995;154(3):998-1006.
49. Fisch P, Malkovsky M, Kovats S, Sturm E, Braakman E, Klein BS, et al. Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells. Science 1990;250(4985):1269-73.
50. De Libero G. Sentinel function of broadly reactive human gamma delta T cells. Immunol Today 1997;18(1):22-6.
51. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000;96(2):384-92
52. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003;102(6):2310-1.
53. Mariani S, Muraro M, Pantaleoni F, Fiore F, Nuschak B, Peola S, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005;19(4):664-70.
54. Marten A, Lilienfeld-Toal M, Buchler MW, Schmidt J. Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma/delta T cells. J Immunother 2007;30 (4):370-7
55. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bispho-sphonate for cancer immunotherapy. Int JCancer 2005;116(1):94-9
56. Naoe M, Ogawa Y, Takeshita K, Morita J, Shichijo T, Fuji K, et al. Zoledronate stimulates gamma delta T cells in prostate cancer patients. Oncol Res 2010;18 (10):493-501
57. Santini D, Martini F, Fratto ME, Galluzzo S, Vincenzi B, Agrati C, et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009;58(1):31-8.
58. Sugie T, Murata-Hirai K, Iwasaki M, Morita CT, Li W, Okamura H, et al. Zoledronic acid-induced expansion of gammadelta T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunol Immunother 2013;62(4):677-87.
59. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-Associated macro-phages. Crit Rev Oncol Hematol 2008;66(1):1-9.
60. Coffelt SB, Hughes R, Lewis CE. Tumor-Associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796 (1):11-8.
61. Lin EY, Pollard JW. Tumor-Associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007;67(11):5064-6.
62. Rogers TL, Wind N, Hughes R, Nutter F, Brown HK, Vasiliadou I, et al. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Cell Oncol (Dordr) 2013;36 (6):505-14.
63. Moreau MF, Guillet C, Massin P, Chevalier S, Gascan H, Basle MF, et al. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 2007;73(5):718-23.
64. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP. Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macro-phage infiltration in tumor stroma. Cancer Res 2007;67(23):11438-46.
65. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zoledronic acid repolarizes tumour-Associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010;14(12):2803-15.
66. Ha TC, Li H. Meta-Analysis of clodronate and breast cancer survival. Br JCancer 2007;96(12):1796-801.
67. Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008;47(4):740-6.
68. Mystakidou K, Katsouda E, Parpa E, Kelekis A, Galanos A, Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005;22 (2):195-201.
69. Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010;11(5):421-8.
70. Rack B, Juckstock J, Genss EM, Schoberth A, Schindlbeck C, Strobl B, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010;30(5):1807-13.
71. Lin AY, Park JW, Scott J, Melisko M, Goga A, Moasser MM, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008;26(S15):S559.
72. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005;25(3):144-51.
73. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, et al. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep 2006;15(5):1351-7.
74. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007;13(15 Pt 1):4482-6.
75. Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, et al. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res Treat 2010;124(3):733-43.
76. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, et al. Zoledronic-Acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005;69(1):35-43.
77. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases. Med Oncol 2008;25(3):346-9.
78. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol 2010;161(2):290-7.
79. Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadelta T cells: a phase I clinical study. J Immun-other 2011;34(2):202-11.
80. Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, et al. Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother 2011;60(10):1447-60.
81. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9(9):840-9.
82. Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-Associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008;13(5):503-14.
83. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010;21(11):2188-94.
84. De Boer R., Bundred N., Eidtmann H., Llombart A., Neven P., von Minckwitz G., et al. The effect of zoledronic acid on aromatase inhibitor-Associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. In: Proceedings of the 33rd annual San Antonio breast cancer symposium; 2010. p. 8-12.
85. Coleman R.E., Thorpe H.C., Cameron D., Dodwell D., Burkinshaw R., Keane M., et al. Adjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04)(abstract S4-S5). In: Proceedings from the San Antonio breast cancer symposium. San Antonio; 2010.
86. Gnant M. Zoledronic acid in breast cancer: latest findings and interpretations. Ther Adv Med Oncol 2011;3(6):293-301
87. Scagliotti GV, Kosmidis P, de Marinis F, Schreurs AJ, Albert I, Engel-Riedel W, et al. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. Ann Oncol 2012;23(8):2082-7.
88. Aft RL, Naughton M, Trinkaus K, Weilbaecher K. Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Br J Cancer 2012;107(1):7-11.
89. Karim SM, Brown J, Zekri J. Efficacy of bisphosphonates and other bone-Targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers. Clin Adv Hematol Oncol 2013;11(5):281-7.